Home Compare ALB vs MRNA
Stock Comparison · Structural lead, mixed market

Albemarle vs Moderna: Which Stock Looks Stronger in 2026?

Albemarle holds the cleaner structural position, with valuation as the main driver and growth adding further support. Moderna still has the edge on growth, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.

Updated 2026-05-17

The result is anchored in valuation, but profitability also reinforces the same direction. Albemarle Corporation leads by 17 points on the overall comparison score.

Trajectory Similarity
0.61
Moderately similar
Peer-set rank: #14
within Albemarle Corporation's functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.

Most of the shared profile comes through investment intensity.

Similarity drivers
investment intensity
What reduces the match
margin consistency
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
ALB
Albemarle Corporation
53
Peer-Score
Signal qualitylow
Peer basis: S&P 500
vs
MRNA
Moderna, Inc.
36
Peer-Score
Signal qualitylow
Peer basis: S&P 500

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: ALB vs MRNA Profitability 35 13 Stability 23 17 Valuation 83 30 Growth 63 100 ALB MRNA
Gap Ranking
#1 Valuation +53
#2 Growth +37
#3 Profitability +22
#4 Stability +6
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for ALB and MRNA Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer ALBMRNA Relative valuation Structural strength

Albemarle Corporation and Moderna, Inc. look relatively close on structure, but the price setup still leans toward Albemarle Corporation.

Valuation position uses Forward P/E and peer-relative valuation score where available.

Entry today — historical context

Where ALB and MRNA each sit in their own 5-year price and valuation history.

BASED ON 5-YEAR HISTORY ALB Neutral · below norm 0th 50th 100th 32 pct gap MRNA Lower · below norm 0th 50th 100th 59th 26th
Today MRNA sits in the lower-middle of its own 5-year history (26th percentile), while ALB sits higher in its own history (59th). Within each stock's own 5-year context, MRNA is at a historically more favourable entry position than ALB. This reflects entry timing, not which company is structurally stronger — peer-relative analysis is a separate question addressed above.

Describes historical entry positioning only. Descriptive — not investment advice.

Relative Position vs Comparable Companies
Valuation
On valuation, Albemarle Corporation ranks near the top of the group; Moderna, Inc. sits in the weaker half.
Growth
On growth, the edge is clear — both rank well, but Moderna, Inc. sits noticeably higher.
Valuation — Dominant Gap
ALB
83
MRNA
30
Gap+53in favour of ALB

The main spread comes from a meaningfully cheaper peer-relative valuation.

What keeps the gap from being one-sided

Moderna still pushes back on growth by a very wide margin, which keeps the read from becoming one-way.

What this means for the comparison

Valuation settles the comparison, while pricing and growth keep the broader setup from looking fully aligned.

Explore full peer positioning in AssetNext

Break down the ALB vs MRNA comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how ALB and MRNA each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.